Investment case
Cullinan Therapeutics, Inc.
CLNN · 2 developments mapped · last assessed 2026-09-24
Market Ontology has mapped 2 macro, policy, and market developments to Cullinan Therapeutics, Inc. since 2026-09-15. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for CLNN yet, so no modelled value is shown. The CLNN valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run CLNN on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Main threat
Clene Inc. Follow-On — $4M
Dilution of existing shareholders, potential downward pressure on share price due to increased supply, and signaling effect of raising capital at a relatively low price.
· Moves shares outstanding, equity value per share
- Open question
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology
Direct impact of clinical trial data readouts on company valuation and future prospects. Positive data could lead to increased investor confidence, potential partnerships, or accelerated development. Negative data could have the opposite effect.
· Moves probability of success for pipeline assets, peak sales estimates for cln 978, velinotamig, cln 049, discount rate reflecting perceived risk
What changed, by assumption
- 2026-09-24Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology
- 2026-09-15Clene Inc. Follow-On — $4M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-16 | Share count | Bullish | The company is issuing 1,219,513 new shares through a registered direct offering, which will increase the total share count and cause dilution. | 0.90 |
| 2026-09-16 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-09-16 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-24 | Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology | watch | 3-12m | 0.90 |
| 2026-09-15 | Clene Inc. Follow-On — $4M | Bearish | 1-3m | 0.70 |